Sep 2026· Journal of Controlled Release· pp.
115363
· 0 citations· 166 references
Medicine
TL;DR
This review examines luminal targeting strategies (secretion pathway-mediated loading, lipoprotein anchoring, and membrane scaffold fusions), surface display platforms, and genetic yield-enhancement mechanisms to advance bEVs toward clinically viable, programmable delivery systems.
Abstract
Bacterial extracellular vesicles (bEVs) are nanoscale, membrane-bound particles naturally secreted by bacteria and are increasingly being explored as therapeutic carriers. Their small size, ability to encapsulate and protect cargo, inherent bioactivity, and compatibility make them attractive candidates for therapeutic development. However, precise and reproducible functionalization remains a central challenge for clinical translation. Post-isolation physical and chemical modification methods enable cargo loading and surface conjugation but are often limited by membrane disruption, heterogeneous functionalization, and scale-up constraints. In contrast, genetic engineering approaches program vesicle composition during biogenesis, enabling controllable luminal loading, surface display, and hypervesiculation. In this review, we examine luminal targeting strategies (secretion pathway-mediated loading, lipoprotein anchoring, and membrane scaffold fusions), surface display platforms (ClyA, Lpp-OmpA hybrids, autotransporters, and ice nucleation protein), and genetic yield-enhancement mechanisms. Finally, we outline key translational considerations to advance bEVs toward clinically viable, programmable delivery systems.
Bacterial membrane vesicles (BMVs) are nanoscale vesicles that are naturally released by bacteria into the extracellular environment. By retaining the bacterium's membrane and luminal cargo, BMVs represent natural nanocarriers and long-distance messengers capable of influencing human health and disease progression. Dep...
Giulia E. Stewart, Yi-Tong Guo, Shi-Jie Cao· Journal of Controlled Releas...· 0 citations
Extracellular vesicles (EVs) are membrane-bound, nano-sized particles released by diverse cell types. They serve as key mediators of intercellular communication by transporting a broad repertoire of proteins, lipids, nucleic acids, and metabolites to recipient cells within a protective lipid bilayer. Owing to their nat...
Nawaz Khan, Zeynab Ahmadova, Yu-Jie Shi et al.· Molecular Biomedicine· 1 citation
This review examines recent advances in LbL-engineered LBNs, focusing on how multilayer surface architecture reshapes physicochemical properties, cargo localization and release, biological identity, cellular interactions, and transport across physiological barriers.
Eunseo Jang, Gaeun Lee, Yoseph Seo et al.· Pharmaceutics· 0 citations
Delivering therapeutic macromolecules to defined cell populations in vivo remains a central unsolved problem in biomedicine. Proteins, nucleic acids and viral vectors are cleared by phagocytes, degraded by enzymes, blocked by endothelial and interstitial barriers, and trapped in acidifying endolysosomes. Pre-existing i...
Extracellular vesicle (EV) therapeutics are progressing from broad proof-of-concept studies toward product-specific engineering and clinically defined applications. Native EVs offer biological membrane functions and the capacity to transport diverse molecular cargoes, but their therapeutic performance is limited by low...
Jiao Xu, Zhi Li, Da Liu et al.· Extracellular Vesicles and C...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.